Publication:

A gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen Recognition

Loading...
Thumbnail Image

Date

2013

Journal Title

Journal ISSN

Volume Title

Publisher

Public Library of Science
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Lutje Hulsik, David, Ying-ying Liu, Nika M. Strokappe, Simone Battella, Mohamed El Khattabi, Laura E. McCoy, Charles Sabin, et al. 2013. A gp41 MPER-specific llama vhh requires a hydrophobic CDR3 for neutralization but not for antigen recognition. PLoS Pathogens 9(3): e1003202.

Abstract

The membrane proximal external region (MPER) of the HIV-1 glycoprotein gp41 is targeted by the broadly neutralizing antibodies 2F5 and 4E10. To date, no immunization regimen in animals or humans has produced HIV-1 neutralizing MPER-specific antibodies. We immunized llamas with gp41-MPER proteoliposomes and selected a MPER-specific single chain antibody (VHH), 2H10, whose epitope overlaps with that of mAb 2F5. Bi-2H10, a bivalent form of 2H10, which displayed an approximately 20-fold increased affinity compared to the monovalent 2H10, neutralized various sensitive and resistant HIV-1 strains, as well as SHIV strains in TZM-bl cells. X-ray and NMR analyses combined with mutagenesis and modeling revealed that 2H10 recognizes its gp41 epitope in a helical conformation. Notably, tryptophan 100 at the tip of the long CDR3 is not required for gp41 interaction but essential for neutralization. Thus bi-2H10 is an anti-MPER antibody generated by immunization that requires hydrophobic CDR3 determinants in addition to epitope recognition for neutralization similar to the mode of neutralization employed by mAbs 2F5 and 4E10.

Description

Research Data

Keywords

Biology, Biophysics, Biomacromolecule-Ligand Interactions, Macromolecular Assemblies, Microbiology, Immunity, Adaptive Immunity, Immunizations, Virology, Viral Structure, Viral Envelope, Antivirals, Immunodeficiency Viruses, Viral Vaccines, Microbial Pathogens

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories